Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review

Show other versions (1)

Bibliographic Details
Main Authors:	Prakash Peddi, Runhua Shi, Binu Nair, Fred Ampil, Glenn M. Mills, Syed H. Jafri
Format:	Article
Language:	English
Published:	SAGE Publishing 2015-01-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/cisplatin-cetuximab-and-radiation-in-locally-advanced-head-and-neck-sq-article-a4590

Similar Items

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
by: Prakash Peddi, et al.
Published: (2015-01-01)

Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
by: Avinash Khadela, et al.
Published: (2023-01-01)

FEASIBILITY OF INDUCTION DOCETAXEL, CISPLATIN, 5-FLUOROURACIL, CETUXIMAB (TPF-C) FOLLOWED BY CONCURRENT CETUXIMAB RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
by: Nikolaos eCharalambakis, et al.
Published: (2013-01-01)

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
by: Il Seok Daniel Jeong, et al.
Published: (2020-08-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
by: Olivia Leblanc, et al.
Published: (2020-02-01)

Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
by: Himani Aggarwal, et al.
Published: (2020-06-01)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01)

RETRACTED: Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
by: Yanqing Zheng PhD, et al.
Published: (2021-05-01)

Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Published: (2023-07-01)

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
by: Muge Akmansu, et al.
Published: (2010-12-01)

Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
by: S Griffin, et al.
Published: (2009-06-01)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
by: Federica Iannelli, et al.
Published: (2020-08-01)

Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
by: Won Jong Jin, et al.
Published: (2020-11-01)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
by: Georgios Tsakonas, et al.
Published: (2020-10-01)

The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council
Published: (2019-01-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
by: Hélène Carinato, et al.
Published: (2021-10-01)

Investigating the role of ADAM10 and ADAM17 in cetuximab resistance in head and neck squamous cell carcinoma
by: Kareemaghay, S
Published: (2014)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
by: Chi T Viet, et al.
Published: (2014-01-01)

Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
by: Meng-Che Hsieh, et al.
Published: (2021-10-01)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01)

Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment
by: Kah Yee Goh, et al.
Published: (2022-04-01)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
by: Schmitz Sandra, et al.
Published: (2015-03-01)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
by: Mohamedtaki A Tejani, et al.
Published: (2010-06-01)

Cetuximab: its unique place in head and neck cancer treatment
by: Specenier P, et al.
Published: (2013-04-01)

Modified bi‐weekly cetuximab‐cisplatin and 5‐FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients
by: Amichay Meirovitz, et al.
Published: (2022-03-01)

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
by: Ramon Andrade de Mello, et al.
Published: (2014-01-01)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
by: Dirk Rades, et al.
Published: (2023-06-01)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
by: Ana Belén Griso, et al.
Published: (2022-02-01)

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response
by: Justine De Azevedo, et al.
Published: (2022-09-01)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
by: Chuan-Chien Yang, et al.
Published: (2022-05-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
by: Kunal eSaigal, et al.
Published: (2014-06-01)

Efficiency of Cisplatin Based Concurrent Chemoradiation in Stages III & IV Head & Neck Squamous Cell Carcinoma
by: Syeda Uzma Naqvi, et al.
Published: (2016-08-01)

Efficiency of Cisplatin Based Concurrent Chemoradiation in Stages III & IV Head & Neck Squamous Cell Carcinoma
by: Syeda Uzma Naqvi, et al.
Published: (2016-08-01)

Efficiency of Cisplatin Based Concurrent Chemoradiation in Stages III & IV Head & Neck Squamous Cell Carcinoma
by: Kulsoom Begum, et al.
Published: (2016-08-01)